SCHEMBL3560897

SCHEMBL3560897

CC(C)(C)OC(=O)/C(=C/Nc1ccc(I)cc1)C(=O)c1ccccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
DHODH Q02127 2/20 0.37
NPSR1 Q6W5P4 3/20 0.36
ADRB2 P07550 1/20 0.34
ADRB1 P08588 1/20 0.34
ADRB3 P13945 1/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPT P10636 2/20 0.34
RECQL P46063 1/20 0.34
CYP11B1 P15538 3/20 0.33
SMO Q99835 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
HTT P42858 2/20 0.33
CYP11B2 P19099 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
TSHR P16473 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3560898 1.00 CES2 (0.38) CES2CES1DHODHNPSR1ADRB2
SCHEMBL5175842 0.92 KDM4E (0.35) CES2CES1DHODHNPSR1ADRB2
SCHEMBL3573718 0.88 CES2 (0.41) CES2CES1DHODHNPSR1KDM4E
SCHEMBL3570531 0.88 CES2 (0.41) CES2CES1DHODHNPSR1KDM4E
SCHEMBL3568685 0.85 DHODH (0.55) DHODHNPSR1KDM4EMAPTRECQL
SCHEMBL3566832 0.85 DHODH (0.55) DHODHNPSR1KDM4EMAPTRECQL
SCHEMBL3574491 0.82 CES2 (0.45) CES2CES1MAPTSMOTDP1
SCHEMBL3574492 0.82 CES2 (0.45) CES2CES1MAPTSMOTDP1
SCHEMBL3571085 0.81 CES2 (0.41) CES2CES1DHODHMAPTSMO
SCHEMBL3557140 0.80 CES2 (0.41) CES2CES1DHODHMAPTCYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1742904-B1 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF UNIV CALIFORNIA (US) 2012-10-31 EP disclosed
US-7825278-B2 Substituted enaminones, their derivatives and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-11-02 US disclosed
US-20080064748-A1 Substituted enaminones, their derivatives and uses thereof OXFORD FINANCE CORPORATION 2008-03-13 US disclosed
EP-1742904-A4 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF UNIV CALIFORNIA (US) 2007-04-18 EP disclosed
EP-1742904-A2 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-01-17 EP disclosed
WO-2005108347-A2 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064748-A1 Substituted enaminones, their derivatives and uses thereof GABRB2, GABRB1, GABRB3 CES2 1007/4885CES1 1398/4885DHODH 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.